|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu
LZ, Sun Y, Lin AH, Liu MZ and Ma J: How does intensity-modulated
radiotherapy versus conventional two-dimensional radiotherapy
influence the treatment results in nasopharyngeal carcinoma
patients? Int J Radiat Oncol Biol Phys. 80:661–668. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xiao WW, Huang SM, Han F, Wu SX, Lu LX,
Lin CG, Deng XW, Lu TX, Cui NJ and Zhao C: Local control, survival,
and late toxicities of locally advanced nasopharyngeal carcinoma
treated by simultaneous modulated accelerated radiotherapy combined
with cisplatin concurrent chemotherapy: Long-term results of a
phase 2 study. Cancer. 117:1874–1883. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brennecke J and Cohen SM: Towards a
complete description of the microRNA complement of animal genomes.
Genome Biol. 4:2282003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carthew RW and Sontheimer EJ: Origins and
Mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kang M, Xiao J, Wang J, Zhou P, Wei T,
Zhao T and Wang R: MiR-24 enhances radiosensitivity in
nasopharyngeal carcinoma by targeting SP1. Cancer Med. 5:1163–1173.
2016. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin T, Zhou F, Zhou H, Pan X, Sun Z and
Peng G: MicroRNA-378g enhanced radiosensitivity of NPC cells
partially by targeting protein tyrosine phosphatase SHP-1. Int J
Radiat Biol. 91:859–866. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao L, Tang M, Hu Z, Yan B, Pi W, Li Z,
Zhang J, Zhang L, Jiang W, Li G, et al: miR-504 mediated
down-regulation of nuclear respiratory factor 1 leads to
radio-resistance in nasopharyngeal carcinoma. Oncotarget.
6:15995–16018. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miller TE, Ghoshal K, Ramaswamy B, Roy S,
Datta J, Shapiro CL, Jacob S and Majumder S: MicroRNA-221/222
confers tamoxifen resistance in breast cancer by targeting p27Kip1.
J Biol Chem. 283:29897–29903. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rao X, Di Leva G, Li M, Fang F, Devlin C,
Hartman-Frey C, Burow ME, Ivan M, Croce CM and Nephew KP:
MicroRNA-221/222 confers breast cancer fulvestrant resistance by
regulating multiple signaling pathways. Oncogene. 30:1082–1097.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee JC, Zhao JT, Clifton-Bligh RJ, Gill A,
Gundara JS, Ip JC, Glover A, Sywak MS, Delbridge LW, Robinson BG
and Sidhu SB: MicroRNA-222 and microRNA-146b are tissue and
circulating biomarkers of recurrent papillary thyroid cancer.
Cancer. 119:4358–4365. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li W, Guo F, Wang P, Hong S and Zhang C:
miR-221/222 confers radioresistance in glioblastoma cells through
activating AKT independent of PTEN status. Curr Mol Med.
14:185–195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F,
Xiao Y, Guang-Xiu W, Zhi-Fan J, Pei-Yu P, Qing-Yu Z and Chun-Sheng
K: MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell
proliferation and radioresistance by targeting PTEN. BMC Cancer.
10:3672010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamada KM and Araki M: Tumor suppressor
PTEN: Modulator of cell signaling, growth, migration and apoptosis.
J Cell Sci. 114:2375–2382. 2001.PubMed/NCBI
|
|
21
|
Wang Y, Guo Z, Shu Y, Zhou H, Wang H and
Zhang W: BART miRNAs: An unimaginable force in the development of
nasopharyngeal carcinoma. Eur J Cancer Prev. 26:144–150. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamashita R, Sato M, Kakumu T, Hase T,
Yogo N, Maruyama E, Sekido Y, Kondo M and Hasegawa Y: Growth
inhibitory effects of miR-221 and miR-222 in non-small cell lung
cancer cells. Cancer Med. 4:551–564. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang DQ, Zhou CK, Jiang XW, Chen J and
Shi BK: Increased expression of miR-222 is associated with poor
prognosis in bladder cancer. World J Surg Oncol. 12:2412014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hwang MS, Yu N, Stinson SY, Yue P, Newman
RJ, Allan BB and Dornan D: miR-221/222 targets adiponectin receptor
1 to promote the epithelial-to-mesenchymal transition in breast
cancer. PLoS One. 8:e665022013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Quintavalle C, Garofalo M, Zanca C, Romano
G, Iaboni M, del Basso De Caro M, Martinez-Montero JC, Incoronato
M, Nuovo G, Croce CM and Condorelli G: miR-221/222 overexpession in
human glioblastoma increases invasiveness by targeting the protein
phosphate PTPu. Oncogene. 31:858–868. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wong QW, Ching AK, Chan AW, Choy KW, To
KF, Lai PB and Wong N: MiR-222 overexpression confers cell
migratory advantages in hepatocellular carcinoma through enhancing
AKT signaling. Clin Cancer Res. 16:867–875. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang S and Yu D: PI(3)king apart PTEN's
role in cancer. Clin Cancer Res. 16:4325–4330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cai LM, Lyu XM, Luo WR, Cui XF, Ye YF,
Yuan CC, Peng QX, Wu DH, Liu TF, Wang E, et al: EBV-miR-BART7-3p
promotes the EMT and metastasis of nasopharyngeal carcinoma cells
by suppressing the tumor suppressor PTEN. Oncogene. 34:2156–2166.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou XM, Sun R, Luo DH, Sun J, Zhang MY,
Wang MH, Yang Y, Wang HY and Mai SJ: Upregulated TRIM29 promotes
proliferation and metastasis of nasopharyngeal carcinoma via
PTEN/AKT/mTOR signal pathway. Oncotarget. 7:13634–13650. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hafsi S, Pezzino FM, Candido S, Ligresti
G, Spandidos DA, Soua Z, McCubrey JA, Travali S and Libra M: Gene
alterations in the PI3K/PTEN/AKT pathway as a mechanism of
drug-resistance (review). Int J Oncol. 40:639–644. 2012.PubMed/NCBI
|
